Quick Summary
Berirab P 300IU Injection
Last updated on 26 Sep 2026 | 08:43 AM (IST)
₹5366
MRP: ₹6639.49
(You Save ₹1273.49)
1 PREFILLED SYRINGE(s) OF 2ML
Berirab P 300IU Injection
Salt Composition
HUMAN RABIES IMMUNOGLOBULINMarketer
BHARAT SERUMS & VACCINES LTD
Prepaid Only. Non-Returnable.
19% OFF
₹5366
MRP: ₹6,639.49
Inclusive of all taxes
19% Off
Salt Composition
HUMAN RABIES IMMUNOGLOBULINMarketer
BHARAT SERUMS & VACCINES LTD
Prepaid Only. Non-Returnable.
Dispatch: Today
Care delivered without the wait. Your order is prioritized for rapid dispatch to ensure it reaches your doorstep on time.
Introduction to Berirab P 300IU Injection
Berirab P 300 IU Injection contains the active agent Human Rabies Immunoglobulin (HRIG). It is indicated to prevent passive, transient rabies infection after exposure to a rabid animal (dogs, mongoose, jackals, foxes). This injection is formulated from blood plasma from screened donors. Rabies infection spreads when a person is bitten, scratched, or licked by an infected animal, especially when the skin is already injured. Rabies is a serious and often fatal viral disease that can cause severe neurological symptoms, including fever, headache, muscle weakness, and paralysis. Once symptoms develop, the disease is almost always fatal. Though this infection is 100% fatal, it is 100% preventable with timely measures and the correct use of available vaccines, immunoglobulins, or monoclonal antibodies.
People with a history of severe allergic reactions to Berirab P 300IU Injection or any of its components should not receive this medication. This injection is prepared from human plasma and may contain infectious agents that can cause disease. Report to your physician immediately if you experience symptoms like headache, nausea, fever, vomiting, weakness, muscle pain, or diarrhea, as these symptoms indicate a possible viral infection. Pediatric patients require special considerations regarding the use of Berirab P 300IU Injection. It can be used in elderly individuals, but the dose and administration may need to be adjusted based on age, weight, and health status.
Uses of Berirab P 300IU Injection
- Prevention of rabies infection post-exposure to a rabid animal
Therapeutic Effects of Berirab P 300IU Injection
The therapeutic effect of Berirab P 300IU Injection is to prevent or treat rabies infection. It works by providing immediate, passive immunity to the rabies virus by neutralizing the virus before it can infect the body's cells and cause disease. It is usually given along with the rabies vaccine, which helps the body develop its own antibodies against the virus.
Interaction of Berirab P 300IU Injection with other drugs
Inform your healthcare provider about all your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Berirab P 300IU Injection, reducing effectiveness by causing undesirable side effects.
More Information about Berirab P 300IU Injection
- Store in a refrigerator between 2°C to 8°C (36°F to 46°F).
- Keep away from moisture, heat, and light.
- It should not be frozen.
- Keep it in its original packaging until it is ready to be used.
- Keep out of the reach of children and pets.
How to consume Berirab P 300IU Injection
Berirab P 300IU Injection is administered as an injection, usually by a healthcare professional. The injection is typically given into the muscle or at the site of the bite wound.
Safety Advice for Berirab P 300IU Injection
Breast Feeding
It is unknown if Berirab P 300IU Injection is excreted in human breast milk, so breastfeeding women should consult a healthcare provider before taking the injection.
Alcohol
individuals should avoid consuming alcohol before or immediately after receiving Berirab P 300IU Injection, as alcohol can impair the immune system and potentially reduce the effectiveness of the treatment.
Liver
Patients with preexisting liver disease should talk to their healthcare provider before taking it.
Lungs
In individuals with lung conditions such as asthma or chronic obstructive pulmonary disease (COPD), Berirab P 300IU Injection can cause shortness of breath or worsen respiratory symptoms.
Driving
Patients should always monitor their response to the Berirab P 300IU Injection medication and be cautious when driving or operating machinery if they experience any side effects that may impair their ability to do so safely.
Pregnancy
Pregnant women should consult their healthcare provider about their pregnancy status before receiving Berirab P 300IU Injection.
Side Effects of Berirab P 300IU Injection
Berirab P 300IU Injections cause some side effects like all medications, although not everyone will experience them.
Serious:
- Severe allergic reactions
- Respiratory distress
- Blood pressure changes
- Seizures or convulsions
- Chest pain
- Unusual warmth of limb
Common:
- Pain, swelling, or redness at the injection site
- Fever
- Headache
- Nausea
- Dizziness
Word of Advice
It is important to carefully read and understand the warnings and precautions associated with the medication. Patients should report to the doctor if they have any infusion reactions. Pregnant and breastfeeding women should consult with a healthcare provider before taking it. Be sure to inform your healthcare provider of any allergies, medical conditions, or medications you take. Berirab P 300IU Injection may also interfere with the immune response to live virus vaccines, and there is a small risk of transmitting blood-borne infections. Always maintain a healthy and balanced diet to support your overall health and well-being.
FAQs about Berirab P 300IU Injection
Q1.
Can Berirab P 300IU Injection prevent rabies infection?
Berirab P 300IU Injection is not a vaccine and cannot prevent rabies infection. It is used to provide immediate passive immunity to individuals exposed to rabies who may not yet have developed their immune response. A rabies vaccine is typically given with Berirab P 300IU Injection to provide long-term protection against rabies.
Q2.
Can Berirab P 300IU Injection be given to individuals with compromised immune systems?
Berirab P 300IU Injection can be given to individuals with compromised immune systems who have been exposed to rabies. However, it is important to consult with a healthcare provider before receiving this medicine, as these individuals may be at a higher risk of developing adverse reactions.
Q3.
Can Berirab P 300IU Injection be given to individuals who have already received a rabies vaccine?
Berirab P 300IU Injection may be given to individuals who have already received a rabies vaccine as a part of post-exposure prophylaxis. However, the timing of the vaccine and Berirab P 300IU Injection administration may differ depending on the individual's vaccination history and the severity of the exposure.
Q4.
Can Berirab P 300IU Injection be given to individuals who have received blood transfusions or blood products?
Berirab P 300IU Injection may interfere with the immune response to live virus vaccines, including measles, mumps, rubella, and varicella. Therefore, individuals who have received blood transfusions or products should consult with a healthcare provider before receiving this injection to determine the appropriate timing of any live virus vaccines.
Q5.
Can Berirab P 300IU Injection be given to individuals with a history of Guillain-Barré syndrome?
Berirab P 300IU Injection may be associated with some individuals' increased risk of Guillain-Barré syndrome. Therefore, individuals with a history of Guillain-Barré syndrome should consult a healthcare provider before receiving this injection.
Q6.
How long does the protective effect of Berirab P 300IU Injection last?
The protective effect of Berirab P 300IU Injection varies depending on the individual's immune response and the severity of the rabies exposure. It provides immediate passive immunity, but the duration of protection is limited. A rabies vaccine is typically given with this injection to provide long-term protection against rabies.
Fact Box of Berirab P 300IU Injection
Molecule name: Human Rabies Immunoglobulin | Therapeutic class: Immunizing agent |
Pharmacological class: Immunoglobulins | Indications: Treatment of COVID-19 |
References
- Bio Products Laboratory Limited, Electronic Medicines Compendium (EMC), [Revised on Sep 2020] [Accessed on 10th May 2023], https://www.medicines.org.uk/emc/files/pil.5543.pdf
- Kedrion Biopharma Inc., US Food & Drug Administration, [Revised on 2020] [Accessed on 10th May 2023], https://www.fda.gov/media/106795/download
- Sudarshan MK. World Health Organization 2018 Guidelines on Rabies Prophylaxis: Contentious Issues. Pediatr Inf Dis 2019;1(4):154–156, https://www.pidjournal.com/doi/PID/pdf/10.5005/jp-journals-10081-1226
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr. Archana Gupta
BDS
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 26 Sep 2026 | 08:43 AM (IST)
Want to know more?
Read Our Editorial Policy
